Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• Autori principali: Xiaomin Wan (Autore), Xiaohui Zeng (Autore), Liubao Peng (Autore), Ye Peng (Autore), Qiao Liu (Autore), Lidan Yi (Autore), Xia Luo (Autore), Qijian Deng (Autore), Chongqing Tan (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...